{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:25:08Z","timestamp":1747149908868,"version":"3.40.5"},"reference-count":18,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Arrhythmia"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation evaluated use of nonvitamin K antagonist oral anticoagulant edoxaban vs enoxaparin\u2010warfarin in patients with nonvalvular atrial fibrillation undergoing electrical cardioversion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Hypothesis<\/jats:title><jats:p>To assess clinical factors related to successful or unsuccessful cardioversion. To evaluate whether differences in adverse events based on anticoagulation strategy may exist.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this multicenter prospective randomized open\u2010label blinded end\u2010point evaluation trial, 2199 patients were randomized to edoxaban 60\u00a0mg once daily (30\u00a0mg for creatinine clearance 15\u201050\u00a0mL\/min, weight\u00a0\u2264\u00a060\u00a0kg, and\/or concomitant use of P\u2010glycoprotein inhibitor) or enoxaparin\u2010warfarin. Successful cardioversion was confirmed by 12\u2010lead electrocardiography\u2010documented sinus rhythm.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cardioversion was successful in 1578 patients; in 355 patients, cardioversion was unsuccessful. Male, high body weight, high body mass index (BMI), coronary artery disease, concomitant aspirin, or prior statins use were more common in patients with unsuccessful cardioversion; international normalized ratio control did not differ by cardioversion success. On multivariate analysis, gender (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.05), body weight (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.0196) and BMI (<jats:italic>P<\/jats:italic>\u00a0=\u00a0.0377) emerged as independent predictors of successful cardioversion. There were no significant differences in primary efficacy (a composite of stroke, systemic embolic event, myocardial infarction, and cardiovascular death during overall study period) regardless of cardioversion success. There were no significant differences in bleeding rates, regardless of cardioversion outcome; notwithstanding low numbers, edoxaban and enoxaparin\u2010warfarin did not differ.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Male gender, higher mean weight and higher mean BMI were associated with unsuccessful cardioversion. Efficacy and safety outcomes were low and did not differ by cardioversion success.<\/jats:p><\/jats:sec>","DOI":"10.1002\/joa3.12341","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T14:01:19Z","timestamp":1586959279000},"page":"430-438","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE\u2010AF) randomized trial"],"prefix":"10.1002","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"first","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Merino","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz Universidad Europea Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[{"name":"Department of Hypertension Medical Univeristy of Lodz Lodz Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naab","family":"Al\u2010Saady","sequence":"additional","affiliation":[{"name":"Covance Inc. Osprey House Littlewick Green UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Jin","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development Basking Ridge NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Melino","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Pharma Development Basking Ridge NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Winters","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo, Inc. Basking Ridge NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-1975","authenticated-orcid":false,"given":"Monika","family":"Kozie\u0142","sequence":"additional","affiliation":[{"name":"Liverpool Centre for Cardiovascular Science University of Liverpool and Liverpool Heart &amp; Chest Hospital Liverpool UK"},{"name":"Department of Cardiology, Congenital Heart Diseases and Electrotherapy Division of Medical Sciences in Zabrze Medical University of Silesia Zabrze Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Goette","sequence":"additional","affiliation":[{"name":"St Vincenz Hospital Paderborn Germany"},{"name":"Working Group: Molecular Electrophysiology University Hospital Magdeburg Magdeburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.71.838.457"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31474-X"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.02.009"},{"key":"e_1_2_6_5_1","unstructured":"National Institute for Health and Care Excellence.Atrial fibrillation: the management of atrial fibrillation(clinical guideline 180).2014.https:\/\/www.nice.org.uk\/guidance\/cg180Accessed April 13 2020"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.71.46"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22931"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/pace.12561"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.04.030"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euw161"},{"key":"e_1_2_6_11_1","article-title":"Clinical importance of atrial cardiomyopathy","author":"Hammwohner M","year":"2018","journal-title":"Int J Cardiol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.2001.1389"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.11.026"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2261-14-99"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.891049"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2018.11.019"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2005.03.057"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.4960240313"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2011.11.005"}],"container-title":["Journal of Arrhythmia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjoa3.12341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12341","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/joa3.12341","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/joa3.12341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T10:11:55Z","timestamp":1693995115000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/joa3.12341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/joa3.12341"],"URL":"https:\/\/doi.org\/10.1002\/joa3.12341","archive":["Portico"],"relation":{},"ISSN":["1880-4276","1883-2148"],"issn-type":[{"type":"print","value":"1880-4276"},{"type":"electronic","value":"1883-2148"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"2020-02-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}